• +1-646-491-9876
    • +91-20-67278686

    Search

    Middle East Respiratory Syndrome Pipeline Review H1 2017

    Middle East Respiratory Syndrome Pipeline Review H1 2017

    • Report Code ID: RW0001858667
    • Category Pharmaceuticals
    • No. of Pages 56
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

    Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERSCoV) . Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Middle East Respiratory Syndrome (MERS) - Overview
    Middle East Respiratory Syndrome (MERS) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
    Atriva Therapeutics GmbH
    Autoimmune Technologies LLC
    Fab'entech SA
    Gilead Sciences Inc
    Humabs BioMed SA
    Inovio Pharmaceuticals Inc
    Nanotherapeutics Inc
    NanoViricides Inc
    Novavax Inc
    Phelix Therapeutics LLC
    Planet Biotechnology Inc
    Regeneron Pharmaceuticals Inc
    Romark Laboratories LC
    Middle East Respiratory Syndrome (MERS) - Drug Profiles
    3B-11 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATR-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNSP-333S1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSW-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FBR-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FM-2101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-5734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INO-4500 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LCA-60 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome coronavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome coronavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitazoxanide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3048 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3051 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAB-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Middle East Respiratory Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East Respiratory Syndrome (MERS) - Product Development Milestones
    Featured News & Press Releases
    Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300
    Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
    Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment
    Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Middle East Respiratory Syndrome (MERS) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Fab'entech SA, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Nanotherapeutics Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Planet Biotechnology Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1 2017

    List of Figures

    Number of Products under Development for Middle East Respiratory Syndrome (MERS) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Atriva Therapeutics GmbH
    Autoimmune Technologies LLC
    Fab'entech SA
    Gilead Sciences Inc
    Humabs BioMed SA
    Inovio Pharmaceuticals Inc
    Nanotherapeutics Inc
    NanoViricides Inc
    Novavax Inc
    Phelix Therapeutics LLC
    Planet Biotechnology Inc
    Regeneron Pharmaceuticals Inc
    Romark Laboratories LC

    Request for Sample

    Report Url http://www.reportsweb.com//middle-east-respiratory-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//middle-east-respiratory-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//middle-east-respiratory-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments